Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Investigator Choice (IC) Chemotherapy

PreclinicalSmall molecule

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric Cancer or Gastroesophageal Junction AdenocarcinomaRecruiting

Gastric Cancer or Gastroesophageal Junction AdenocarcinomaPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT07552402

Clinical

Trials by Indication[1]

Cervical Cancer1 trial

Study of Cemiplimab in Adults With Cervical Cancer

Completed· Regeneron logo

Regeneron·Phase 3·NCT03257267·608 enrolled

Gastric Cancer or Gastroesophageal Junction Adenocarcinoma1 trial

Paclitaxel Oral Solution Plus Fruquintinib Versus Investigator's Choice as Second-Line Treatment for Advanced Gastric Cancer: A Multicenter, Open-Label, Randomized Controlled Trial

Recruiting·HHarbin Medical University·Preclinical·NCT07552402·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Investigator Choice (IC) Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Investigator Choice (IC) Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Investigator Choice (IC) Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Regeneron

Related News